Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

被引：271
作者：
Kampan, Nirmala Chandralega [1 ,2 ]
Madondo, Mutsa Tatenda [1 ]
McNally, Orla M. [2 ,3 ]
Quinn, Michael [2 ,3 ]
Plebanski, Magdalena [1 ]
机构：
[1] Monash Univ, Dept Immunol, The Alfred, Melbourne, Vic 3181, Australia
[2] Royal Womens Hosp, Gynaeoncol Unit, Melbourne, Vic 3052, Australia
[3] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic 3052, Australia
来源：
BIOMED RESEARCH INTERNATIONAL | 2015年 / 2015卷
关键词：
REGULATORY T-CELLS; PHASE-III TRIAL; DOCOSAHEXAENOIC ACID-PACLITAXEL; ADVANCED EPITHELIAL OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; PRIMARY PERITONEAL CANCER; INTRAVENOUS CISPLATIN PLUS; ALBUMIN-BOUND PACLITAXEL; DOSE-DENSE PACLITAXEL; MULTIDRUG-RESISTANCE;
D O I：
10.1155/2015/413076
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
引用
收藏
页数：21
相关论文
共 162 条
[1]  
Abu-Rustum N. R., 1997, SEMIN ONCOL, V24
[2]   Role of hypoxia in tumor angiogenesis - molecular and cellular angiogenic crosstalk [J].
Acker, T ;
Plate, KH .
CELL AND TISSUE RESEARCH, 2003, 314 (01) :145-155
[3]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[4]   Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe [J].
Aggarwal, Bharat B. ;
Vijayalekshmi, R. V. ;
Sung, Bokyung .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :425-430
[5]   Immune responses to p53 in patients with cancer:enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites [J].
Albers, AE ;
Ferris, RL ;
Kim, GG ;
Chikamatsu, K ;
DeLeo, AB ;
Whiteside, TL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) :1072-1081
[6]   Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species [J].
Alexandre, Jerome ;
Hu, Yumin ;
Lu, Weiqin ;
Pelicano, Helene ;
Huang, Peng .
CANCER RESEARCH, 2007, 67 (08) :3512-3517
[7]   Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer [J].
Ando, Masashi ;
Yonemori, Kan ;
Katsumata, Noriyuki ;
Shimizu, Chikako ;
Hirata, Taizo ;
Yamamoto, Harukaze ;
Hashimoto, Kenji ;
Yunokawa, Mayu ;
Tamura, Kenji ;
Fujiwara, Yasuhiro .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) :457-465
[8]  
ARAO S, 1994, CANCER RES, V54, P1355
[9]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[10]  
Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre (Australia), 2010, CANC SER
12345678910